Everforth Inc quarterly report, Q3 FY2016

On Assignment, Inc. — Form 10-Q Summary

Reporting period: Quarter ended September 30, 2016; filed November 8, 2016. The filing identifies the issuer as On Assignment, Inc., rather than Everforth Inc. Unless otherwise noted, financial amounts below are in millions of dollars.

Business context and results

On Assignment provides professional staffing and consulting services through its Apex and Oxford segments, primarily in technology, life sciences, and creative markets. The Physician Segment was sold in February 2015 and is reported as discontinued operations.

MetricQ3 2016Q3 2015Nine months 2016Nine months 2015
Revenue$629.4$572.1$1,819.5$1,487.5
Gross profit$207.1$191.4$597.0$485.8
Operating income$55.4$51.5$143.9$109.2
Income from continuing operations$29.8$24.9$73.1$52.2
Net income$29.8$24.9$73.2$78.3
Diluted EPS$0.55$0.47$1.36$1.48

Q3 revenue increased 10.0% year over year; nine-month reported revenue rose 22.3%. On a pro forma basis, treating the 2015 acquisitions as if completed at the start of 2014, nine-month revenue increased 13.6%. Q3 gross margin was 32.9%, down 0.6 percentage points year over year; nine-month reported gross margin was 32.8%, while the pro forma comparison showed a 0.6-point decline. Q3 SG&A was $142.0 million, or 22.6% of revenue. Nine-month operating cash flow was $140.3 million, versus $87.3 million a year earlier.

Liquidity, debt, and capital allocation

  • At September 30, 2016, cash and cash equivalents were $17.0 million, including $9.8 million held abroad that management said it did not intend to repatriate. Working capital was $260.4 million.
  • Long-term debt was $658.6 million net of unamortized loan costs; principal outstanding was $675.0 million. The weighted-average interest rate was 3.5%. The company had $142.5 million available under its revolving credit facility.
  • The debt covenant leverage ratio was 2.38 to 1.00 against a 4.00-to-1.00 maximum at quarter-end. The company reported compliance with all covenants. A 100-basis-point change in rates would affect annual interest expense by approximately $6.8 million, based on debt outstanding at quarter-end.
  • For the nine months, investing activities used $15.3 million, including $20.6 million for property and equipment and $6.0 million received from release of escrow proceeds on the Physician Segment sale. Financing activities used $132.1 million, principally for $106.0 million of debt principal payments, $21.5 million of stock repurchases, and contingent consideration payments.
  • The board authorized repurchases of up to $150.0 million over two years. Through September 30, the company had repurchased 607,911 shares for $22.6 million; $127.4 million remained authorized.

Material changes and management commentary

  • Q3 growth was led by Apex, with revenue up 12.0%; Oxford revenue increased 4.3%. Management cited strong demand at Apex Systems’ large customer accounts and growth at Creative Circle. Oxford growth reflected key accounts, healthcare IT projects, and European IT operations.
  • Q3 gross-margin compression reflected a lower permanent-placement mix and faster growth in higher-volume, lower-margin accounts. Oxford permanent-placement revenue weakened amid lower demand from technology clients, longer hiring decisions, and a tight candidate pool.
  • Nine-month revenue and gross profit comparisons were affected by the full-period inclusion of Creative Circle, acquired in June 2015. Reported nine-month net income declined from 2015 largely because the prior-year period included a $25.7 million after-tax gain on the Physician Segment sale; continuing-operations income increased.
  • On August 5, 2016, a credit-facility amendment reduced the Term B loan interest rate by 25 basis points. The company recorded $0.9 million of related third-party fees in interest expense.
  • Management said expected cash flows and revolving-credit availability should meet obligations, working-capital needs, and capital expenditures for the next 12 months. The filing provides no specific earnings or revenue guidance.
  • Risks highlighted include demand and economic conditions, attracting and retaining staffing consultants and qualified professionals, competition, growth management, information systems, acquisition integration, litigation, foreign-currency movements, and variable interest rates. Management said pending ordinary-course legal matters were not expected to have a material effect. Workers’ compensation reserves depend on actuarial estimates and claims experience.

Important facts for investors to verify

  • Confirm issuer identity and filing attribution: the supplied filing is for On Assignment, Inc., although the request metadata names Everforth Inc.
  • Track organic/pro forma growth and the contribution of Creative Circle, as reported growth includes acquisition effects.
  • Monitor gross-margin trends, permanent-placement demand, and Oxford’s hiring and candidate-market conditions.
  • Review debt reduction, interest-rate exposure, covenant headroom, and the availability of revolving credit.
  • Assess cash generation against repurchases, capital expenditures, and remaining contingent or other obligations; confirm the effect of cash held abroad.
  • Distinguish continuing-operations performance from prior-period discontinued-operation gains when comparing net income and EPS.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.